Paysign, Inc. (NASDAQ:PAYS) EVP Sells $100,394.40 in Stock

Key Points

• EVP Joan M. Herman of Paysign, Inc. sold 14,160 shares on August 4th for approximately $100,394.40, reducing her ownership by 1.69% and leaving her with about 821,583 shares valued at $5.83 million.
• Paysign's stock price increased to $7.16 on August 4th, with a market cap of $388.22 million and a 1-year trading range between $1.80 and $8.88.
• Analysts have set price targets for Paysign ranging from $8.00 to $9.00, with ratings indicating buying interest from firms such as LADENBURG THALM/SH SH and Lake Street Capital.

Paysign, Inc. (NASDAQ:PAYS - Get Free Report) EVP Joan M. Herman sold 14,160 shares of Paysign stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $7.09, for a total transaction of $100,394.40. Following the transaction, the executive vice president directly owned 821,583 shares of the company's stock, valued at approximately $5,825,023.47. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Paysign Price Performance

Shares of PAYS traded up $0.02 during midday trading on Monday, hitting $7.16. The stock had a trading volume of 949,589 shares, compared to its average volume of 954,471. The firm has a market cap of $388.22 million, a PE ratio of 65.10 and a beta of 0.78. Paysign, Inc. has a 1 year low of $1.80 and a 1 year high of $8.88. The stock's 50 day moving average is $6.45 and its 200 day moving average is $3.93.

Paysign (NASDAQ:PAYS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. Paysign had a net margin of 9.55% and a return on equity of 19.49%. The company had revenue of $18.60 million during the quarter, compared to analysts' expectations of $17.49 million. As a group, equities research analysts expect that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Paysign

Several institutional investors and hedge funds have recently added to or reduced their stakes in PAYS. PDT Partners LLC purchased a new stake in shares of Paysign during the fourth quarter worth $39,000. R Squared Ltd purchased a new stake in shares of Paysign in the second quarter valued at about $108,000. Wells Fargo & Company MN grew its holdings in shares of Paysign by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 15,385 shares of the company's stock valued at $46,000 after purchasing an additional 5,243 shares during the period. Royce & Associates LP grew its holdings in shares of Paysign by 36.5% in the first quarter. Royce & Associates LP now owns 19,319 shares of the company's stock valued at $41,000 after purchasing an additional 5,166 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Paysign in the first quarter valued at about $51,000. Hedge funds and other institutional investors own 25.89% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. DA Davidson set a $8.00 target price on shares of Paysign in a report on Friday, June 13th. LADENBURG THALM/SH SH upped their price target on shares of Paysign from $7.25 to $8.25 and gave the stock a "buy" rating in a research report on Friday, May 9th. Finally, Lake Street Capital upped their price target on shares of Paysign from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.